Holen Sie sich die Stockscreener-App
2.49
0.40%
0.01
Vorhandelsmarkt:
2.49
Schlusskurs vom Vortag:
$2.48
Offen:
$2.52
24-Stunden-Volumen:
47,940
Relative Volume:
0.31
Marktkapitalisierung:
$13.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.92M
KGV:
-0.0989
EPS:
-25.1834
Netto-Cashflow:
$-22.74M
1W Leistung:
-2.73%
1M Leistung:
+7.33%
6M Leistung:
-79.11%
1J Leistung:
-90.42%
1-Tages-Spanne:
$2.465
$2.54
1-Wochen-Bereich:
$2.425
$2.5938
52-Wochen-Spanne:
$1.79
$28.61
Moleculin Biotech Inc Stock (MBRX) Company Profile
Firmenname
Moleculin Biotech Inc
Sektor
Branche
Telefon
713-300-5160
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
2.49 | 13.29M | 0 | -23.92M | -22.74M | -25.18 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-09 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
Why did MBRX stock climb 14% today? - MSN
MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
MBRX Forecast, Price Target & Analyst Ratings | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Moleculin Biotech files to sell 6.37M shares of common stock for holders - MSN
Moleculin Biotech Announces Annamycin Significantly Extends Survival in Preclinical Pancreatic Cancer Models at AACR 2026 - Minichart
Moleculin Highlights Promising Preclinical Data for L-ANN - TipRanks
Moleculin Biotech, Inc. Reports Promising Preclinical Results for Annamycin in Pancreatic Cancer Treatment - Quiver Quantitative
[8-K] Moleculin Biotech, Inc. Reports Material Event - Stock Titan
In pancreatic cancer models, Moleculin drug stretched survival to 29 days - Stock Titan
Moleculin Biotech, Inc. Announces Poster Presentation at ASCO 2026 Highlighting Cardiac Safety of Annamycin - Quiver Quantitative
Cancer drug heart-safety data earns Moleculin an ASCO poster slot - Stock Titan
Moleculin Biotech stock (US60855L2034): Is its oncology pipeline strong enough to drive investor ret - AD HOC NEWS
Moleculin Biotech stock (US60855L2034): Is its cancer drug pipeline strong enough to drive investor - AD HOC NEWS
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moleculin Biotech Stockholders Approve Warrant Share Issuance - TipRanks
Moleculin Biotech shareholders approve warrant issuance, reject name change By Investing.com - Investing.com India
Moleculin Biotech shareholders approve warrant issuance, reject name change - Investing.com
Shareholders at Moleculin (NASDAQ: MBRX) back 6.37M-share warrant plan - Stock Titan
[EFFECT] Moleculin Biotech, Inc. SEC Filing - Stock Titan
Form 10-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]: [Amend] - ADVFN
Moleculin Biotech | 10-K/A: Annual report (Amendment) - Moomoo
Moleculin Biotech (NASDAQ: MBRX) details 2025 leadership, pay and ownership - Stock Titan
Moleculin Biotech (NASDAQ: MBRX) registers 6.37M resale shares via warrants - Stock Titan
Will Moleculin Biotech Inc benefit from geopolitical trends2026 Stock Rankings & Momentum Based Trading Ideas - baoquankhu1.vn
Momentum Shift: Will Moleculin Biotech Inc benefit from geopolitical trendsStop Loss & Technical Confirmation Trade Alerts - baoquankhu1.vn
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile - Sahm
Is Moleculin Biotech (MBRX) Stock entering maturity stage | Price at $2.41, Up 3.88%Trending Social Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile - Bitget
Tangible book value per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin Biotech Stock: Advancing Cancer Therapies Amid Clinical Milestones and Biotech Volatility - AD HOC NEWS
MBRX Stock Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Meme Stocks: What are Moleculin Biotech Incs earnings expectations2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
Total debt per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin Biotech Stock: Clinical-Stage Biotech Focused on Oncology Innovations for North American I - AD HOC NEWS
Moleculin Biotech (NASDAQ: MBRX) registers 6.37M resale shares tied to warrants - Stock Titan
Scalable Biotech Manufacturing Unlocks a $14B Market - Benzinga
Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Sell Signal: Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Moleculin at Roth Conference: Annamycin’s Market Potential By Investing.com - Investing.com Canada
Moleculin at Roth Conference: Annamycin’s Market Potential - Investing.com
MBRX: Annamycin's phase III AML trial nears key data, highlighting strong efficacy and zero cardiotoxicity - TradingView
MBRX: Annamycin's phase III AML trial nears key data, highlighting its efficacy and safety advantages - TradingView
MBRX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus
Moleculin enrolls 45th patient in pivotal AML trial By Investing.com - Investing.com Canada
Moleculin Biotech Reports 40% Remission Rate in Early Phase 3 AML Study for Annamycin, Accelerating Toward 90 Patient Enrollment 12 - Minichart
Moleculin Biotech (MBRX) Advances Phase 2B/3 Trial for Acute Mye - GuruFocus
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout - Bitget
Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout - tipranks.com
Moleculin enrolls 45th patient in pivotal AML trial - investing.com
Moleculin Biotech, Inc. Prepares for Key Interim Results in Pivotal AML Trial with 40% Early Remission Rate - Quiver Quantitative
Moleculin Hits 45-Subject Milestone, Sets Mid-2026 MIRACLE Interim Readout - TradingView
Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):